Homocysteine, Cobalamin and Folate Status and their Relations to Neurocognitive and Psychological Markers in Elderly in Northeastern Iran

Lida Manavifar¹, Habibollah Nemati Karimooy*², Jamshid Jamali³, Morteza Talebi doluee⁴, Abbas Shirdel ⁵, Amireh Nejat shokohi ⁶, Mahdie Fatemi nayyeri ⁷

1 Department of Laboratory Sciences Technology, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Neurology and Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4 Department of Emergency Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Department of Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6 Birjand University of Medical Sciences, Birjand, Iran

ARTICLE INFO
Article type: Original article

Article history:
Received: May 26, 2012
Accepted: Aug 19, 2012

Keywords:
Cobalamin
Folate
Homocystein
Psychological
Neurocognitive
The elderly

ABSTRACT

Objective(s): Incidence of neurocognitive and psychological disorders may be related to serum homocystein (Hcy), cobalamin (vitamin B₁₂) and folate levels in old people. The aim of this study was to assess the relationship between Hcy, cobalamin, folate and neurocognitive and/or psychological disorders in the elderly.

Materials and Methods: In this cross-sectional study, 280 subjects with ≥ 65 years old, were evaluated. The subjects were selected from 12 regions of Mashhad, Iran, over March to October 2009. After blood sampling, data were collected by questionnaire, face to face interview and performing neurocognitive and psychological tests. The sera of 250 persons were analyzed for cobalamin and folate by RIA method. Amongst the aforementioned samples, 78 cases with cobalamin <300 pg/ml and folate <6.5 ng/ml were analyzed for Hcy by ELISA method.

Results: Amongst the people, 126 (45%) were male and 154 (55%) were female. The prevalence of hyperhomocysteinemia (HHcy) was 59.5% and 37.1% in male and female respectively (P-value = 0.049). Hcy inversely correlated to cobalamin (r=−0.282, P=0.014) and to folate (r=−0.203, P=0.014). Hcy, cobalamin and folate correlations to neurocognitive and psychological impairments were not statistically significant.

Conclusion: Hyper Hcy or low cobalamin and folate in the elderly, are prevalent but their relationships with neurocognitive and psychological impairments is controversial. If these relationships had been confirmed, performing a single serum Hcy or cobalamin test would have been enough to diagnose and prevent neurocognitive impairments and inversely, neurocognitive-psychological sign and symptoms could have meant probable tissue vitamin deficiencies. However methods of assessing neurocognitive and psychological markers with validity and reliability of clinical and laboratory tests for finding aforementioned relationships should be revised.

Introduction

Annually many old people refer to physicians or clinics with mild and vague symptoms such as anemia and neurocognitive and psychological impairments that may be due to cobalamin and folate deficiency followed by gastric atrophy and malnutrition.

Two enzymatic reactions dependent on cobalamin (Cbl), has been identified of which one converts methionyl–coenzyme A to succinyl-CoA using adenosyl-cobalamin as a cofactor. So Cbl deficiency will increase methylmalonyl-CoA as methymalonic acid (MMA). The other enzyme reaction has role in the synthesis of methionine from homocysteine (Hcy) using methyl-cobalamin as a cofactor which is important for definition the neurocognitive and/or psychological aspects of cobalamin and folate deficiency. Both Deficiencies involve in production of tetra Hydrofolatet and cause megaloblastic changes in red blood cells (1).

The common symptoms of cobalamin and folate deficiency are anemia, macrocytosis and neurologic...
symptoms such as parenthesis, ataxia, dementia, depression and psychosis (2). Frequently neurologic progression occurs before hematologic symptoms (3).

Hyper homocysteinemia is caused by various conditions including cobalamin and folate deficiency, renal failure, genetic defects, decreased blood volume and hyperthyroidism. These are independent risk factors for nervous degeneration and cardiovascular and cerebrovascular disorders in old people and thus require special medical management (4-6). Patients with vascular disease have higher plasma levels of homocysteine than patients without vascular disease which indicates vascular risk factors may play a role in the development of cognitive impairments (7).

Cobalamin and folate deficiencies are involved in pathogenesis of cognitive status in old people through hyper homocysteinemia. High levels of homocysteine due to vitamin B deficiency (folate, vitamin B12 and B6, which are required in methylation of homogystein to methionin) correlate with decline cognitive performance (8). However vitamin B supplementation influences are controversial and only a few cognitive tests have shown statistically significant improvements (9).

Up to 15% of old population in the United States and Europe have elevated methylmalonic acid that is associated with low or borderline levels of serum cobalamin (10). Folate deficiency in Sweden was reported up to 20% (11). In a survey in low income Population in South West region of Tehran, Iran, age-adjusted incidence of low serum cobalamin was 27.2% in female and 26.32% in male. Moreover, low serum folate level was 97.92% in female and 98.67% in male (12). A study in United Kingdom showed increasing deficiency from about 1 in 20 among people aged 65-74 years to 1 in 10 among people aged 75 years or older (5).

In the past 10 years, studies have shown high incidence of neurocognitive and/or psychological disorders in Iran (13). In a psychiatric interview on a sample of Iranian population at the age 18 and older, the prevalence of psychiatric disorders was 10.81%. The prevalence of anxiety and mood disorders were 8.35% and 4.29%, respectively. Prevalence of psychotic disorders was 0.89%, neurocognitive disorders 2.78% and dissociative disorders 0.77% (14). According to geriatric depression scale (GDS), 23.5% of old people (60-96 years old) living in Razavi Khorasan province in Iran, are at risk of depression (15).

Regarding to the prevalence of neurocognitive and psychological impairments, hyperhomocysteinemia, cobalamin and folate deficiency in the elderly, assessments for finding relationships between mentioned deficiencies and impairments have been performed, which showed controversial results. By confirming aforementioned relationships, diagnostic and preventative operations might be suggested for the improvement of neurocognitive-psychological impairments in old peoples. Well maintenance of cognitive ability in the elderly is vital not only to provide suitable health status but also to retard the onset of dementia, prevent its progression, increase productivity and decline societal costs for taking care of these people (8).

**Material and Methods**

In this cross-sectional study with cooperation of statistic unit of Khorasan province health centre, 280 male and female, over 65 years old, were selected amongst twelve regions of Mashhad. Seven statistic questioner students selected to call and obtain written informed consent to participants and fill a demographic questionnaire. 250 cases were referred to central laboratory in Emam Reza hospital on March to October 2009. Medical history, medications, smoking habits, vitamin supplement uptake and lifestyle habits were taken from all participants in a face-to-face interview by a practitioner. Also physical and clinical sign and symptoms and results of neurocognitive and psychological tests including mini-mental state exam (MMSE), deep tendon reflex (DTR), Romberg test, geriatric depression scale (GDS), insomnia, motivation, easily crying, pain perception and also persons documents for dementia were recorded in a special form.

Exclusion criteria in participant were creatinine >1.5 mg/dl, B vitamin Supplementation (vitamin B12, B6 and folic acid) in recent 3 months, smoking, medication with metformin, trimetoprim and omeprazole. Elderly with more than 65 years and completed data in questionnaires and forms were included in our study. After blood sampling, sera were collected and kept in -20°C until measuring. Serum cobalamin and folate analyzed by RIA method (DRG kits Cat#, RIA-1990, Germany) Serum methylmalonic acid (MMA) often increases with cobalamin deficiency while homocysteine increases with both folate and cobalamin deficiency, conclusively assayng of serum homocysteine was preferred (16-17). 78 cases, who had cobalamin <300 pg/ml and folate < 6.5ng/ml and also no confounders were analyzed for homocystein by Elisa method (DRG kit Cat#: EIA-2925, Germany).

According to a study on the same population by authors, a cut off point <330 pg/ml and <6.5 ng/ml was selected as cobalamin and folate deficiency respectively. In the same study, hyperhomocysteinemia defined as >15 µmol/l.

**Statistical analysis**

Statistical analysis was conducted using the SPSS version 11.5. Normally distributed quantitative variables were demonstrated as mean ± standard deviation. The normality condition of the quantitative variables was investigated by using the Shapiro-Wilks test. Mann-Whitney and Kruskal-Wallis Tests were used to compare the means of serum cobalamin, folate and homocystein in...
The percentage of elderly with homocysteine higher than 15 µmol/L was 59.5% in men, 37.1% in women and 49.4% in overall.

The mean of serum cobalamin when homocystein serum level was upper than 15 µmol/L was 190.93±69.77 pg/ml with confidence interval of 167.66-214.19. The mean level of folat was 4.11±1.20 ng/ml with confidence interval of 3.70-4.52 when homocystein serum level was upper than 15 µmol/L study showed significant association between serum cobalamin and folate (r=0.559, P<0.001) and negative association between serum homocystein with cobalamin (r=-0.282, P=0.014) and folate (r=-0.203, P=0.014).

For observing the relation between serum homocystein, cobalamin, folate and neurocognitive and/or psychological signs in the elderly, we used Kruskal Wallis test and post-hoc test using Mann-Whitney tests with Bonferroni correction which showed no significant difference between these groups.

Table 1. Average distribution of serum cobalamin, folate and homocystein by sex

|                  | N (% ) | Mean (SD) | Pvalue |
|------------------|--------|-----------|--------|
| Cobalamin (pg/ml)|        |           |        |
| Men              | 107 (43.85%) | 244.74 (232.28) | 0.001  |
| Women            | 137 (56.15%) | 343.020 (451.51) |        |
| Total            | 244    | 299.92 (374.19) |        |
| Folate (ng/ml)   |        |           |        |
| Men              | 107 (44.40%) | 4.96 (3.47) | 0.012  |
| Women            | 134 (55.60%) | 5.60 (3.08) |        |
| Total            | 241    | 5.31 (3.27) |        |
| Homocystein (µmol/L) |      |           |        |
| Men              | 42 (54.55%) | 18.52 (8.81) | 0.015  |
| Women            | 35 (45.45%) | 13.86 (6.27) |        |

Results

Participants included were 126 male (45%) and 154 female (55%). The average age was 72.09±7.5 years.

The mean of cobalamin, folate and homocystein serum was 257.88±182 pg/ml, 5.31±3.27 ng/ml and 15.77±7.27 µmol/L respectively. Men had higher cobalamin and homocystein concentrations than women but the mean level of serum cobalamin, folate and homocystein was not statistically associated to sex.

Table 2. Average distribution of cobalamin, folate and homocystein serum by neurocognitive and psychological markers

| Tests results | N (% ) | Mean (SD) | Pvalue |
|---------------|--------|-----------|--------|
| Cobalamin (mmol/l) |  |           |        |
| Positive (≤20)  | 50 (21.28) | 356.13 (681.21) | 0.737  |
| Negative (>20)  | 185 (78.72) | 288.05 (243.79) |        |
| Folate (ng/ml)  |        |           |        |
| Positive (≤20)  | 50 (21.37) | 5.20 (3.27) | 0.407  |
| Negative (>20)  | 184 (78.63) | 5.35 (3.31) |        |
| Homocystein (µmol/L) |      |           |        |
| Positive (≤20)  | 15 (20.83) | 17.91 (8.18) | 0.267  |
| Negative (>20)  | 57 (79.17) | 15.69 (7.94) |        |
| Dementia        |        |           |        |
| Positive (≥5)   | 47 (21.66) | 310.63 (314.81) | 0.965  |
| Negative (<5)   | 170 (78.34) | 302.24 (411.49) |        |
| Geriatric depression scale (GDS) |  |           |        |
| Positive (≥5)   | 47 (21.76) | 3.50 (3.68) | 0.292  |
| Negative (<5)   | 169 (78.24) | 3.53 (3.30) |        |
| Homocystein     |        |           |        |
| Positive (≥5)   | 12 (17.39) | 15.32 (7.53) | 0.652  |
| Negative (<5)   | 57 (82.61) | 16.38 (8.25) |        |
| Cobalamin (pg/ml) |  |           |        |
| Positive        | 3 (1.88) | 277.66 (99.08) | 0.593  |
| Negative        | 157 (98.12) | 319.45 (444.25) |        |
| Romberg test    |        |           |        |
| Positive        | 3 (1.89) | 5.43 (2.65) | 0.785  |
| Negative        | 156 (98.11) | 5.60 (3.71) |        |
| Homocystein     |        |           |        |
| Positive        | 55 (98.21) | 15.31 (7.41) | 0.370  |
| Normal          | 139 (86.88) | 15.30 (8.25) |        |
| Deep tendon reflex (DTR test) |  |           |        |
| Positive        | 3 (1.89) | 6.60 (3.63) | N-L.0.574 |
| Low             | 17 (10.69) | 5.62 (2.53) | H-L.0.751 |
| Normal          | 49 (85.96) | 15.83 (7.45) | N-L.0.382 |
| Folate (ng/ml)  |        |           |        |
| High            | 2 (3.51) | 18.41 (4.00) | N-L.0.088 |
| Low             | 6 (10.53) | 10.08 (5.40) | H-L.0.096 |
Continue from previous page

Cobalamin  Normal  176 (96.17)  310.37 (423.31)  0.517
Low  7 (3.83)  268.42 (102.42)  
Vibration  Folate  Normal  175 (96.15)  5.50 (3.58)  0.458
Low  7 (3.85)  5.28 (1.09)  
Homocysteine  Normal  59 (95.16)  15.05 (7.27)  0.358
Low  3 (4.94)  21.19 (12.44)  
Cobalamin  Normal  205 (97.16)  301.47 (401.16)  0.365
Low  6 (2.84)  323.77 (235.83)  
Pain perception  Folate  Normal  204 (97.14)  5.31 (3.29)  0.809
Low  6 (2.86)  5.51 (3.87)  
Homocysteine  Normal  68 (100.00)  15.97 (7.95)  0.008
Low  0 (0.00)  
Cobalamin  Yes  57 (25.33)  320.99 (295.56)  0.56
No  168 (74.67)  297.66 (415.46)  
Insomnia  Folate  Yes  56 (25.00)  5.64 (3.46)  0.469
No  168 (75.00)  5.23 (3.33)  
Homocysteine  Yes  16 (22.22)  14.07 (4.54)  0.503
No  56 (77.78)  16.75 (8.66)  
Cobalamin  Normal  153 (70.51)  302.42 (432.35)  0.002
High  55 (25.3)  324.33 (283.87)  0.565
Low  9 (4.15)  329.22 (297.57)  0.854
Motivation  Folate  Normal  152 (70.37)  5.15 (3.18)  0.565
High  55 (25.46)  5.89 (3.72)  0.277
Low  9 (4.17)  6.43 (4.66)  0.543
Homocysteine  Normal  49 (73.13)  15.26 (7.72)  0.692
High  15 (22.39)  16.78 (8.49)  0.198
Low  3 (4.49)  24.91 (10.05)  0.110
Cobalamin  Yes  20 (81.5)  216.07 (192.73)  0.046
No  206 (91.15)  311.56 (400.48)  
Easily crying  Folate  Yes  20 (8.89)  4.59 (3.50)  0.050
No  205 (91.11)  5.40 (3.34)  
Homocysteine  Yes  2 (2.70)  17.27 (6.78)  0.607
No  72 (97.30)  16.12 (8.05)  

* for comparing the means we used Kruskal-Wallis Test; N-H: comparing normal with high; N-L: comparing normal with low; H-L: comparing high with low

Discussion
The aim of this study, carried out prospectively in an urban elderly population in North East of Iran, was to discovery relationships between neurocognitive psychological impairments and three components of serum: cobalamin (vitamin B12), folate and homocysteine. Previous studies had shown high prevalence of hyperhomocysteinemia (HHcy), cobalamin and/or folate deficiency and cognitive impairments in the elderly (4, 10-11, 18-19). In Eastern Indians and in Iran HHcy has high prevalence, (44.6% and 41.07%) while 17% and 9.5% of population in California and Finland, suffer from this condition respectively (12, 20). Carmel et al reported its prevalence 26.1% for people without renal disorders while half of them had been identified with low cobalamin or folate levels (29).

A study on old population in North East of Iran, with respect to cut off points, showed that the prevalence of cobalamin deficiency with low levels (<122 pg/ml) was 22.7% and with borderline levels (122-330 pg/ml) was 51.8% and the prevalence of folate deficiency with low levels (<3 ng/ml) was 16.7% and with borderline levels was (<6.5 ng/ml) 64.2% (21).

Previous studies have shown correlation between low level of folate and cognitive impairments. The therapeutic response of Alzheimer’s disease to cholinesterase inhibitors is improved by folic acid supplementation (8, 22). Patients with Fluoxetine-resistant major depression disease (MDD) were found to have low serum level of folate (23). Foltein’s minimental test has shown 45% of the elderly with low cobalamin levels have mental disorders (24). In a study by Shahar et al, 640 patients were studied. 50% of old people present in the population had low or borderline levels of serum cobalamin (120-150 pmol/L) which correlates to both cerebrovascular diseases and cognitive disorders (P=0.046) (19). Incidence of vitamin B12 and folic acid deficiency in Venezuelan old people was 26.4% and 43.4% respectively. Also with Foltein’s minimental test, 49% of the elderly had mental disorders and vitamin B12 levels were significantly lower in this group (4). A study has reported that 28% of patients with dementia have high level of serum homocysteine while the level of serum methylmalonic acid (which increases as a result of cobalamin deficiency) was normal (25).

Normal serum homocysteine has been defined as<15 µmol/l (26), or <15 µmol/l (15, 27). Serum methylmalonic acid (MMA) is often increased with result of cobalamin deficiency (25). Serum homocysteine levels were also significantly higher in those with low folate and high homocysteine concentrations (26). It has also been shown that serum folate levels were significantly lower in this group (25).

Supplementation with folic acid significantly improved the performances in all cognitive domains, especially on stem completion and visual integration, which are subtests of Foltein's minimental test in a study reported (28).

In a study by Shahar et al, patients supplemented with folic acid showed significant improvement in the performance of the Foltein’s minimental test (29).

Patients with Fluoxetine-resistant major depression disease (MDD) were found to have low serum level of folate (23). Foltein’s minimental test has shown 45% of the elderly with low cobalamin levels have mental disorders (24). In a study by Shahar et al, 640 patients were studied. 50% of old people present in the population had low or borderline levels of serum cobalamin (120-150 pmol/L) which correlates to both cerebrovascular diseases and cognitive disorders (P=0.046) (19). Incidence of vitamin B12 and folic acid deficiency in Venezuelan old people was 26.4% and 43.4% respectively. Also with Foltein’s minimental test, 49% of the elderly had mental disorders and vitamin B12 levels were significantly lower in this group (4). A study has reported that 28% of patients with dementia have high level of serum homocysteine while the level of serum methylmalonic acid (which increases as a result of cobalamin deficiency) was normal (25). Normal serum homocysteine has been defined as<15 µmol/l (26), or <15 µmol/l (15, 27). Serum methylmalonic acid (MMA) is often increased with result of cobalamin deficiency (25). Serum homocysteine levels were also significantly higher in those with low folate and high homocysteine concentrations (26). It has also been shown that serum folate levels were significantly lower in this group (25).

**Supplementary Table**

| Parameter | Normal | Low | P-value |
|-----------|--------|-----|---------|
| Vibration | 176 (96.17) | 7 (3.83) | 0.517 |
| Homocysteine | 59 (95.16) | 3 (4.94) | 0.358 |
| Cobalamin | 205 (97.16) | 6 (2.84) | 0.365 |
| Pain perception | 204 (97.14) | 6 (2.86) | 0.809 |
| Motivation | 152 (70.37) | 9 (4.17) | 0.565 |
| Homocysteine | 153 (70.51) | 9 (4.15) | 0.543 |
| Cobalamin | 15 (22.39) | 3 (4.49) | 0.110 |
| Pain perception | 206 (91.15) | 20 (8.89) | 0.046 |
| Homocysteine | 205 (91.11) | 205 (91.11) | 0.050 |
| Cobalamin | 72 (97.30) | 72 (97.30) | 0.607 |
populations (28). Like other studies (21, 29) serum homocysteine correlated inversely with serum cobalamin and folate ($P = 0.001$ for both).

**Cut off points for cobalamin and folate deficiency**

Many researchers have determined cut off points for cobalamin and folate deficiency. Figlin et al defined cobalamin deficiency as $<220$ pg/ml with MMA $>0.24 \mu$ mol/l, and folic acid deficiency as $<4.9$ ng/mL with homocysteine $>15$ mol/l (30) and Rajan et al defined cobalamin deficiency equal to 299 pg/ml (31). Walters et al reported elevated MMA and homocysteine associated with cobalamin $<350$ pg/ml and folate level $<3$ ng/ml as cut off point in the elderly women (16). On the basis of a previous study on the participant of this study, we select cut off point $<330$ pg/ml and $<6.5$ng/ml for cobalamin and folate deficiency respectively (21).

**Correlation between cobalamin and folate deficiency and HHcy**

Our study showed significant association between serum cobalamin and folate ($r=559$, $P \leq 0.001$) and a negative association between HHcy and cobalamin ($r=-0.282$, $P=0.014$) and folate ($r=-0.203$, $P=0.014$).

**Correlation between HHcy, cobalamin and folate deficiency with neurocognitive impairments**

HHcy and Cobalamin and folate deficiency are associated with cognitive impairments and dementia in the elderly. They often ingest cobalamin less than 1 µg/day (less than Recommended Dietary Allowance $=2-4 \mu$g/d). Prevalence of HHcy with this Regimen is reported (10). As cognitive impairments are often incurable, investigation of their modifiable risk factors such as HHcy, cobalamin and folate deficiency is recommended (8).

Correlation of HHcy or cobalamin deficiency with neurocognitive dysfunctions is controversial. It is unknown whether HHcy or vitamin deficiency is responsible for neurocognitive impairments (32). Lidballe et al observations on 839 old people have shown that score of cognitive functions as measured by mini-mental state examination and low wellness have significant correlations with markers of cobalamin insufficiency such as low serum cobalamin, high methylmalonic acid, high homocysteine but their causatives are uncertain (28). The findings of Nilsson et al implied that elevated plasma Hcy in old patients with mental illness is mainly associated with the presence of vascular disease and is not related to any specific psychiatric diagnosis (33). Stabler et al found Positive relations but Hvas et al and Negga et al didn’t found any relations between serum methylmalonic acid and neurologic and gastrointestinal symptoms (25, 27, 34). Homocysteine is negatively correlated with neuropsychological scores, but there are little evidences to justify treating cognitive impairment with cobalamin or folate supplement in peoples over 60 years old (25). However one study has shown that folic acid improve therapeutic response of people with Alzheimer’s disease while a few other studies have indicated no effect on cognitive functions (22). Dolatabadi et al showed that folic acid have therapeutic and preventive effects on cognitive impairments and improves memory performance and learning in Alzheimer’s disease (38).

**Correlation between Serum HHcy, cobalamin and folate deficiency and dementia**

In our study, 20.8% (15 persons) of the elderly with cobalamin $<300$ pg/ml and folate $<6.5$ ng/ml and HHcy had dementia. In these patients correlation between dementia and cobalamin, folate deficiency and HHcy was statically insignificant, but elderly with dementia had higher homocystein serum levels (17.91±8.18 µmol/l) than elderly without dementia.

**Correlation between Serum Hcy, cobalamin, folate and MMSE test**

MMSE (Mini mental state examination) is positive in mental disorders. Normal score is $>20$. In our study serum Hcy, cobalamin and folate levels in two groups of positive and negative MMSE test patients had no significant differences, but the elderly with positive MMSE test had higher Hcy level than negative group. This was not in contrast with the findings of Ellison et al (35). Kado et al in 74–79 years old Population (n=880) in 10 European Country found low but significant relation between MMSE score and cobalamin and also Homocysteine (32).

**Correlation between Serum Hcy, cobalamin, folate and geriatric depression scale (GDS)**

Our results showed that serum Hcy, cobalamin and folate average in the 2 groups with positive (score $>5$) and negative (score $\leq 5$) geriatric depression scale test have not significant differences. The same insignificance was observed with Motivation, Insomnia and easily crying.

**Correlation between Serum Hcy, cobalamin, folate and deep tendon reflex (DTR), Romberg test**

We investigate relations between Hcy, cobalamin, folate, and Neurocognitive Markers by deep tendon reflex test and Romberg test. In two tests, relations were insignificant but the elderly with positive and high scores in DTR test had higher homocystein (18.41 µmol/L) than negative. The same insignificant differences were observed with Vibration and Pain perception.

Consistent to results in some studies, we showed that there are not significant relations between neurocognitive-psychological impairments and
hyperhomocysteinemia or cobalamin and folate deficiency in the elderly. 

Correlations between laboratory and clinical markers for these disorders in various studies are heterogeneous and it is reasonable to assume that there are multi factors resulting in these variations including: different etiologies, stage of the disease, degree of manifestation of symptoms, sampling representative the entire population, diversity of tests and measurement techniques. Normal values for serum cobalamin and its metabolites is not established and various criteria, tests, and cutoff points have been used to define cobalamin deficiency (36). Also minimum value that disturbs nervous system functions is not yet recognized (20). Some studies indicate that vitamin B supplementation normalizes plasma Hcy and MMA (methyl malonic acid) levels without any improvement on cognitive performance and they only delay progression of the disease. This may be due to an insufficient dose and duration of supplements, irreversible or vitamin-independent neurocognitive impairments (8, 18, 37, 38).

In this study we carefully collected participant data by biochemical tests and questionnaires and this was probably more accurate than neurocognitive and psychological examinations. It seems these clinical or cognitive tests are not adequate or sensitive enough to detect mild dysfunctions in these disorders.

These problems are consistent to Bjorkegren et al explaining that since the Nercognitive disorders are the first symptoms of cobalamin and folate deficiency, their diagnosis need much qualified instruments and their investigations require enough subjects and appropriate composition of population and correct sampling (11). Christopher et al refer to the sensitivity and specificity of metabolite measurements for milder deficiency status that are uncertain (8).

Conclusion

Due to prevalence of neurocognitive and psychological impairments, hyperhomocysteinemia, cobalamin and folate deficiency in the elderly, finding crucial relationships between mentioned impairments and deficiencies, which seem to be controversial, is essential. By confirming aforementioned relationship, diagnostic and preventative operations could be initiated to improve neurocognitive- psychological impairments for desired peoples. So primarily, methods for assessment of neurocognitive and psychological status and validity and reliability of clinical and laboratory tests should be revised and secondly, longitudinal studies and clinical trials should be performed in old population to determine whether lowering of homocystein or increasing cobalamin and folate levels will improve neurocognitive psychological impairments or not.

Acknowledgment

This study carried out by grant of Deputy Research in Mashhad University of Medical Science, Mashhad, Iran. We appreciate Dr Mirshojaeen helps, psychiatrist assistant of Mashhad University of Medical Sciences for clinical tests and physical examinations.

References

1. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med [Review] 1999; 159:1289-1298.
2. Lee G. Megaloblastic and nonmegaloblastic macrocytic anemias. Wintrobe's clinical hematology. 9th ed. Philadelphia: Lea and Febiger; 1993.p.745-790.
3. Healton EB, Savage DG, Brust J, Garrett T, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine 1991; 70:229.
4. Meertens L, Solano L. Vitamin B12, folic acid and mental function in the elderly. Invest Clin 2005; 46:53-63.
5. Clarke R, Evans JG, Schneede J, Nexo E, Bates C, Fletcher A, et al. Vitamin B12 and folate deficiency in later life. Age Ageing 2004; 33:34-41.
6. Bizheh N, Jaafari M. The effect of a single bout circuit resistance exercise on homocysteine, hs-CRP and fibrinogen in sedentary middle aged men. Iran J Basic Med Sci 2011; 4:568-573.
7. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine and cognition in elderly patients with dementia or other psychogeriatric diseases. Dement Geriatr Cogn Disord 2010; 30:198-204.
8. Agarwal R. Vitamin B12 deficiency & cognitive impairment in elderly population. Ind J Med Res 2011; 134:410-412.
9. Hvas A-M, Juul S, Lauritzen L, Nexo E, Ellegaard J. No effect of vitamin B12 treatment on cognitive function and depression: a randomized placebo controlled study. J Affect Disord 2004; 81:269-273.
10. Stabler SP, Allen RH. Vitamin B12 deficiency as a worldwide problem. Annu Rev Nutr 2004; 24:299-326.
11. Björkegren K, Svärdssudd K. A population-based intervention study on elevated serum levels of methylmalonic acid and total homocysteine in elderly people: results after 36 months of follow-up. J Intern Med 2004; 256:446-452.
12. Fakhhrzadeh H, Ghotbi S, Pourerbrahim R, Nouri M, Heshmat R, Bandarain F, et al. Total plasma homocysteine, folate, and vitamin B12 status in healthy Iranian adults: the Tehran homocysteine survey (2003-2004) /a cross-sectional population based study. BMC Public Health 2006; 6:29.
13. Noorbalaa AA, Bagheri Yazdi SA, Yasamy MT, Mohammad K. Mental health survey of the adult population in Iran. Br J Psychiatry 2004; 184:70-73.
14. Mohammad MR, Davidian H, Noorbalaa AA, Malekafzali H, Naghavi HR, Pourretemad HR, et al. An epidemiological survey of psychiatric disorders in Iran. Clin Pract Epidemiol Mental Health 2005; 1:16.
15. Mokhber N, Majdi M, Salek Haghjatoopoor M. Prevalence of depression in an elderly population in Iran. Eur Psychiatry 2008; 23:S296.
methylmalonic acid in elderly German women. Am J Clin Nutr 2003; 78:765-772.
17. Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabol Clin Exp 1985; 34:1073-1077.
18. Vogel T, Dali-Yousef N, Kaltenbach G, Andres E. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Pract Clin 2009; 63:1061-1067.
19. Shahar A, Feiglin L, Shahar DR, Levy S, Seligsohn U. High prevalence and impact of subnormal serum vitamin B12 levels in Israeli elders admitted to a geriatric hospital. J Nutr Health Aging 2001; 5:124-127.
20. Gharaibeh MY, Gahtan RA, Khabour OF, Alomari MA. Hyperhomocysteinemia, Low Folate, and vitamin B12 Deficiency in Elderly Living at Home and Care Residences: A Comparative Study. Lab Med 2010; 41:410-414.
21. Shirola A, Manaviifar L, Njat Shokohi A, Shakeri MT, Mahjoub M. A study of folate and cobalamin deficiency in elderly by determining a cut-off point with laboratory markers. Med J Mashhad Univ Med Sci 2009; 52:74.
22. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008:CD004514.
23. Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychi 2004; 65:1090.
24. Oh R, Brown DL. Vitamin B12 deficiency. Am Fam Physician 2003; 67:979-986.
25. Nagga K, Rajani R, Mardh E, Borch K, Mardh S, Marcussen J. Cobalamin, folate, methylmalonic acid, homocysteine, and gastritis markers in dementia. Dement Geriatr Cogn Dis 2003; 16:269-275.
26. Solhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteine in an elderly population. JAMA 1993; 270:2693-2698.
27. Hvas AM, Ellegaard J, Nexo E. Increased plasma methylmalonic acid level does not predict clinical manifestations of vitamin B12 deficiency. Arch Internal Med 2001; 161:1534-1541.
28. Lildhalle DL, Fedosov S, Sherliper P, Hin H, Clarke R, Nexo E. Association of cognitive impairment with combinations of vitamin B12-related parameters. Clin Chem 2011; 57:1436-1443.
29. Carmel R, Green R, Jacobsen D, Rasmussen K, Florea M, Azen C. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr 1999; 70:904-910.
30. Figlin E, Chetrit A, Shahar A, Shpilberg O, Zivelin A, Rosenberg N, et al. High prevalences of vitamin B12 and folic acid deficiency in elderly subjects in Israel. Br J Haematol 2003; 123:696-701.
31. Rajan S, Wallace JI, Beresford SA, Brodkin KL, Allen RA, Stabler SP. Screening for cobalamin deficiency in geriatric outpatients: prevalence and influence of synthetic cobalamin intake. Journal of the Am Geriatr Soc 2002; 50:624-630.
32. Kado DM, Karlamangla AS, Huang M-H, Troen A, Rowe JW, Selhub J, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005; 118:161-167.
33. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine is elevated in elderly patients with memory complaints and vascular disease. Dement Geriatr Cogn Dis 2007; 23:321-326.
34. Stabler SP, Lindeman JM, Allen RH. The use of homocysteine and other metabolites in the specific diagnosis of vitamin B12 deficiency. J Nutr 1996; 126:1266S-1272S.
35. Ellinson M, Thomas J, Patterson A. A critical evaluation of the relationship between serum vitamin B12, folate and total homocysteine with cognitive impairment in the elderly. J Hum Nutr Diet 2004; 17:371-383.
36. Bailey RL, Carmel R, Green R, Pfeiffer CM, Cogswell ME, Osterloh J, et al. Monitoring of vitamin B12 nutritional status in the United States by using plasma methylmalonic acid and serum vitamin B12. Am J Clin Nutr 2011; 94:552-561.
37. Lewerin C, Matousek M, Steen G, Johansson B, Steen B, Niksson-Ehle H. Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study. Am J Clin Nutr 2005; 81:1155-1162.
38. Khorram Khorshid MR, Manoochehri M, Nasehi L, Ohadi M, Rahgozar M. Ccr2 Δ32 polymorphisms in patients with late-onset Alzheimer’s disease: a study from Iran (Ccr2-64I And Ccr5 Δ32 polymorphisms in Alzheimer’s disease. Iran J Basic Med Sci 2012; 15:937-944.